Skip to main content
. 2017 Nov 30;9(12):1305. doi: 10.3390/nu9121305

Figure 1.

Figure 1

Doses of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and total omega-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA) from randomised controlled trials on n-3 LCPUFA supplementation and clinical cardiovascular disease (CVD) outcomes. The red line shows that a DHA dose of 500 mg or greater results in significant CVD outcomes. * Significant effects (p < 0.05); # only 140 per group showing a trend towards a significant effect (p = 0.063). Sign means significant and n.s. means not significant.